Zoetis Inc. Reports 3% Revenue Growth to $2.262 Billion in Q1 2026

Zoetis Inc. reported a revenue increase of 3% for the first quarter of 2026, reaching $2.262 billion compared to $2.198 billion in the same period of 2025. The company's net income attributable to Zoetis remained relatively stable at $601 million, down slightly from $602 million year-over-year. Earnings per share (EPS) increased to $1.42, up from $1.34 in the prior year. The growth in revenue was primarily driven by favorable foreign exchange rates, which contributed approximately $76 million, while operational revenue saw a slight decline of 1%.

In terms of expenses, Zoetis experienced a 4% increase in the cost of sales, totaling $641 million, which represented 28.3% of revenue. Selling, general, and administrative expenses rose by 2% to $588 million, while research and development expenses increased by 11% to $180 million, reflecting the company's commitment to innovation and product development. The effective tax rate for the quarter was 20.7%, down from 22.1% in the previous year, attributed to a more favorable jurisdictional mix of earnings.

Strategically, Zoetis announced its intention to acquire Neogen Corporation's animal genomics business, with the deal expected to close in the second half of 2026. This acquisition follows the company's purchase of Veterinary Pathology Group in 2025, which aimed to enhance its diagnostic capabilities. The company continues to focus on expanding its product portfolio, which includes approximately 300 product lines across various species and therapeutic categories.

Operationally, Zoetis reported a decrease in U.S. segment revenue by 8%, primarily due to lower demand for companion animal products amid increased competition. Conversely, the international segment saw a revenue increase of 17%, driven by strong sales in livestock and companion animal products, particularly in emerging markets. The company also noted a decrease in cash and cash equivalents to $1.941 billion from $2.450 billion at the end of 2025, reflecting increased investments and share repurchases.

Looking ahead, Zoetis remains optimistic about its growth prospects, emphasizing its commitment to innovation and strategic acquisitions. The company plans to continue leveraging its diverse product portfolio and expanding its global presence to capitalize on emerging market opportunities. However, it also acknowledges potential risks, including macroeconomic conditions, competitive pressures, and regulatory changes that could impact future performance.